Eisai

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Seed Therapeutics is a biotechnology company dedicated to developing innovative medical drugs aimed at treating severe diseases. The company specializes in research and development, focusing on harnessing and engineering molecules that utilize molecular glues to target proteins previously considered undruggable. By creating novel protein degradation therapeutics, Seed Therapeutics aims to disrupt cancer biology, offering potential benefits to patients across various tumor types.

RecoMed is South Africa’s largest and fastest growing online healthcare booking platform and marketplace. The company’s online booking platform and the marketplace is its core product, and it has developed white-labelled solutions for, among others, Discovery, Medicross (owned by Netcare) and Clicks. RecoMed’s mobile-friendly platform helps patients quickly find and make appointments with a range of healthcare providers, 24/7, without any phone calls or paperwork. RecoMed seamlessly connects doctors and patients in real-time and is a strong consumer and B2B platform business that reaches stakeholders across the healthcare, life insurance and corporate wellness ecosystem.

C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.

Hyku is a biotechnology company focused on developing small molecule therapeutics that utilize precise covalent targeting to address disease-causing proteins. The company employs a unique platform to identify molecules that covalently bind to non-cysteine amino acids, facilitating the creation of innovative medicines. Hyku's approach aims to tackle significant challenges in the treatment of various diseases, including issues related to selectivity, druggability, and resistance. By advancing the science of covalent medicines, Hyku strives to enhance treatment options and improve patient outcomes.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Lifenet Insurance Company is a life insurance provider based in Tokyo, Japan, established in 2006. The company specializes in underwriting a variety of insurance products, including term death, whole life, medical, cancer, and disability insurance. Lifenet also offers health counseling services, catering to the diverse needs of its clientele. Notably, the company sells its products directly to consumers through the Internet, enhancing accessibility and customer engagement.

Tacit Therapeutics is a biotechnology company focused on developing RNA-targeting treatments aimed at repairing mutated genes associated with devastating diseases. Founded in 2021 and located in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative and non-immunogenic approaches for gene modification. By offering a broadly applicable solution, Tacit Therapeutics enables biotechnology professionals to pursue effective treatments for genetic disorders that were previously deemed untreatable, thereby advancing the field of gene therapy.

Arteryex is a company focused on the development of systems and applications within the medical and healthcare sectors. It specializes in the commissioned development of tailored solutions and operates its own applications, including Pashatto Karte and the LEAF app, which supports health management for employees. Additionally, Arteryex has created an enterprise data management platform designed to optimize health management and medical care. This platform utilizes advanced technologies such as blockchain and artificial intelligence to enhance the retrieval and sharing of medical documents. By maximizing data utilization, Arteryex provides access to personal health record-related services for patients, healthcare professionals, and the broader community.

Ractigen Therapeutics is an early-stage pharmaceutical company dedicated to developing first-in-class therapies that selectively restore the expression of therapeutic genes silenced in diseased cells. Founded in 2016 by pioneers in the RNA activation field, the company leverages a groundbreaking discovery from the University of California San Francisco, known as RNA activation (RNAa). Ractigen's innovative approach aims to address diseases stemming from inadequate gene expression, with a focus on central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. The company is building a promising pipeline of candidate medicines to meet significant unmet medical needs.

PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases.

Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.

SOLA Biosciences is focused on advancing healthcare through innovative biotechnological solutions. The company has developed a modular bioreactor named Sola, which enables users to cultivate cells effectively. In addition to this bioreactor, SOLA Biosciences is engaged in the development of transformative gene therapies aimed at treating conformational diseases. Utilizing its proprietary chaperone platform technology, the company targets neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD). By selectively reducing abnormal, disease-causing proteins that accumulate in neuron cells, SOLA Biosciences aims to provide permanent therapeutic options for patients suffering from these debilitating conditions.

Altoida AG is a healthcare company based in Lucerne, Switzerland, established in 2016, focused on developing a platform and application for assessing brain health, particularly in relation to Alzheimer's disease and dementia. The company aims to transform how brain function is measured and neurological diseases are diagnosed, utilizing smartphones and tablets. Its innovative approach leverages over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence. Altoida's flagship product is a Computerized Cognitive Assessment Aid, which is classified as Class II and is exempt from the 510(k) process. This application employs machine learning algorithms to evaluate patients' cognitive and functional abilities, enabling early detection of Alzheimer's and facilitating timely intervention to improve patient outcomes. In recognition of its advanced technology, Altoida received FDA Breakthrough Device Designation in July 2021.

Voluntis, Inc. is a healthcare software company that specializes in developing digital therapeutic solutions across various therapeutic areas, including diabetes and oncology. Founded in 2001 and headquartered in Cambridge, Massachusetts, Voluntis offers products such as Insulia, a prescription medical device that provides insulin dose recommendations and educational coaching for type 2 diabetes patients based on their blood glucose data. Additionally, the company provides Diabeo, a digital solution designed for type 1 and type 2 diabetes patients on a basal-bolus insulin regimen, which determines personalized insulin dosages through tailored algorithmic calculations. With a focus on enhancing patient monitoring and support services, Voluntis has successfully managed over 600,000 patients and deployed more than 50 programs, demonstrating its commitment to improving healthcare outcomes through innovative technology.

Allm Inc. is a Tokyo-based medical ICT company that specializes in developing advanced medical communication platforms aimed at enhancing healthcare delivery. Founded in 2001 and formerly known as SkillUpJapan Corp., Allm offers a suite of applications designed to facilitate communication among healthcare professionals. Key products include Kaigo and Kango, which support home care workers and nurses respectively; MySOS, a first-aid support application; AcaMed, an academic platform for medical research; and FollowUP, a business intelligence tool for real-time management information. Allm's solutions are deployed in over 18 countries, including the United States, Japan, and various regions in Europe, South America, the Middle East, and Africa. The company's innovations aim to improve the efficiency of healthcare services, enhance information sharing, and ultimately contribute to better community care systems.

Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.

Unlearn.AI, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing innovative software tools for clinical research. Established in 2017, Unlearn.AI focuses on enhancing clinical trials through its unique digital twin technology, known as TwinRCT. This approach utilizes machine learning to create prognostic digital twins for individual patients, allowing for more accurate estimations of treatment effects while reducing the number of participants needed. The company also offers services for Clinical Trial Design, which helps determine inclusion criteria, endpoints, and study sizes, as well as Synthetic Control Arms that can minimize or eliminate the need for concurrent control groups. Additionally, Unlearn.AI provides Subgroup Analysis to identify and analyze specific patient subgroups within trial results. By integrating expertise from pharmaceuticals, medical technology, and machine learning, Unlearn.AI aims to transform clinical trials to improve outcomes for both patients and sponsors.

Darmiyan, Inc. is a biotechnology company focused on early detection and monitoring of neurodegenerative diseases, including Alzheimer's disease. Founded in 2014 and based in San Francisco, California, the company has developed a proprietary diagnostic software platform known as BrainSee. This Software as a Service (SaaS) platform utilizes standard clinical brain MRI scans and basic cognitive tests to generate detailed brain maps and quantifications of neurodegeneration in each voxel. BrainSee provides a summary score reflecting an individual's brain health and the likelihood of future cognitive decline, allowing for diagnosis at early stages when treatment options are most effective. The technology, referred to as The Virtual Microscope, employs advanced medical image analysis and artificial intelligence, underpinned by over 40 years of neuroscience research. It has undergone successful third-party validation in the United States and Canada, demonstrating high accuracy and consistency in predicting mild cognitive impairment, and has received endorsements from notable figures in the medical community.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Numab is a biotechnology company focused on developing antibody-based therapeutics for severe diseases, including chronic inflammation and cancer. The company employs a plug-and-play platform that minimizes the randomness typically associated with the drug discovery process, allowing for the predictable creation of multispecific biotherapeutics. This platform facilitates the development of mono- or multispecific antibody fragment-based therapeutics with customized pharmacokinetic properties, enabling the healthcare sector to address multiple therapeutic targets simultaneously. Through its innovative approach, Numab aims to enhance the effectiveness of immunotherapies in treating complex medical conditions.

Allm Inc. is a Tokyo-based medical ICT company that specializes in developing advanced medical communication platforms aimed at enhancing healthcare delivery. Founded in 2001 and formerly known as SkillUpJapan Corp., Allm offers a suite of applications designed to facilitate communication among healthcare professionals. Key products include Kaigo and Kango, which support home care workers and nurses respectively; MySOS, a first-aid support application; AcaMed, an academic platform for medical research; and FollowUP, a business intelligence tool for real-time management information. Allm's solutions are deployed in over 18 countries, including the United States, Japan, and various regions in Europe, South America, the Middle East, and Africa. The company's innovations aim to improve the efficiency of healthcare services, enhance information sharing, and ultimately contribute to better community care systems.

iPS PORTAL, Inc. is a Kyoto-based company established in 2014 that specializes in the development of instruments for analyzing and measuring cells, with a particular focus on induced pluripotent stem (iPS) cell technology. The company offers contract testing services for iPS cells, supporting researchers and healthcare companies in the practical application of this technology. Its services encompass research and development outsourcing, concept planning, and training programs in cell culture, all aimed at facilitating the advancement of drug discovery and regenerative medicine. By promoting the widespread use of iPS cell technology, iPS PORTAL plays a vital role in accelerating research and commercialization efforts within the healthcare sector.

AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.

SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan.

MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications. The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies internationally. MGI PHARMA, INC. was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, INC. in 1990. The company is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI PHARMA, INC. operates as a subsidiary of Eisai Corporation of North America.

Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.